News | April 07, 2008

Medicare Boosts Payment 3.6 Percent to Insurers in Medicare Advantage

April 8, 2008 - The government on Monday said it would raise payments next year to insurers that provide healthcare coverage to seniors by 3.6 percent, a slight increase from last year's boost.

The increase applies to companies in the Medicare Advantage program, the privately run wing of the government health care plan for seniors. Officials from the Centers for Medicare and Medicaid Services said the increase is slightly lower than the estimated 3.7 percent expected growth increase for Medicare in 2009.

Last year the agency increased payments on average by 3.5 percent.

About 22 percent of the 44 million seniors in Medicare receive their benefits from private companies. The government pays insurers a set fee for each enrollee, which varies by the county they live in.

Wall Street was still analyzing the payment increase Monday evening, though it appeared to be lower than some analyst projections.

The 2009 payment rate will serve mainly as a benchmark against which companies offer services, rather than a final payment amount. Companies typically offer to provide Medicare benefits for less than the benchmark because they can use the remaining money to offer additional benefits, including dental and vision care. Those extras can help attract new enrollees.

UnitedHealth is the largest provider of Medicare Advantage with 14 percent of the market and 1.4 million seniors enrolled. Humana has more than 1.25 million seniors in its plans and accounts for about 13 percent of the total market.

Other companies with significant investment in Medicare include HealthSpring Inc., Health Net Inc. and Wellcare Health Plans Inc.

Medicare officials announced Thursday they will begin auditing how insurers bill the government for treating various medical conditions. The government hopes to start adjusting company payments to make up for billing errors by the end of the year.

Democrats in Congress made a push last year to cut payments to private companies in Medicare, pointing out that they cost the government about 13 percent more than traditional Medicare.

On Thursday, unions AFL-CIO, AFSCME and several consumer groups sent a letter to congressional leadership calling on it to curb "excessive corporate subsidies" to private insurers.

"It is fiscally irresponsible for Congress to allow this waste of taxpayer dollars to continue unabated, when money is needed to shore up Medicare's finances," states the letter, which was also signed by Families USA and the Medicare Rights Center.

Despite such prodding by labor and consumer advocates, analysts do not expect another effort to cut payments to the companies. President Bush has vowed to veto any effort by Congress to trim payments to insurers.

The insurance industry has argued that companies use government funding to provide important health care benefits not offered under traditional Medicare.

Shares of Humana Inc. fell 16 cents to $43 in after hours trading, following an earlier close at $43.16. Shares of UnitedHealth Group Inc. fell 13 cents to $36.54 in after-hours trading, following an earlier close at $36.67.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init